The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Publications
Granulomatosis with Polyangiitis Following Pfizer-BioNTech COVID-19 Vaccination.
Modern rheumatology case reports 2022 Mar 04;; — 2022 Mar 04
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination.
Frontiers in immunology 2021;12;762006 — 2021 — 762006
ANCA-associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine.
Kidney international reports 2021 Aug 17;; — 2021 Aug 17
Villa M, Díaz-Crespo F, Pérez de José A, Verdalles Ú, Verde E, Ruiz FA, Acosta A, Mijaylova A, Goicoechea M
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
Kidney international 2021 Aug 17;; — 2021 Aug 17
ANCA-Associated Vasculitis Following the Pfizer-BioNTech COVID-19 Vaccine.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2021 Jul 16;; — 2021 Jul 16